Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 7:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hepatic Encephalopathy Assessment Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems

NCT07023354
View directory record Official record
Conditions
Healthy, Hepatic Impairment
Interventions
BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Rialto, California • Orlando, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease

NCT04940416
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Neurofit (oculometric testing)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy

NCT04816916
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
AXA1665, Placebo
Drug
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
San Francisco, California • DeBary, Florida • Gainesville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Phase 2 Interventional

AST-120 Used to Treat Mild Hepatic Encephalopathy

NCT00867698
View directory record Official record
Conditions
Mild Hepatic Encephalopathy
Interventions
AST-120
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Results available

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

NCT01966419
View directory record Official record
Conditions
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions
ornithine phenylacetate, placebo intravenous infusion
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated Phase 4 Interventional Results available

Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

NCT01890694
View directory record Official record
Conditions
Hyponatremia
Interventions
Tolvaptan, Placebo, Hepatic Encephalopathy Assessment, Quality of Life Assessment, Vital signs, Blood laboratory tests, Ascites Evaluation, Edema
Drug · Behavioral · Biological + 1 more
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated No phase listed Observational

Eye Movement Testing in Patients With Obesity and the Impact of Weight Loss Surgery

NCT04940429
View directory record Official record
Conditions
Bariatric Surgery Candidate, Obesity, Morbid
Interventions
Neurofit, Psychometric hepatic encephalopathy score
Device · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Not applicable Interventional

Telehealth Intervention in Cirrhotics

NCT03969186
View directory record Official record
Conditions
Cirrhosis, Liver, Liver Diseases
Interventions
Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Results available

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

NCT03712280
View directory record Official record
Conditions
Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
Interventions
MNK6106, Rifaximin
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 19, 2026, 7:03 PM EDT
Recruiting No phase listed Observational

Prospective Investigation of Cirrhotic Cardiomyopathy in Humans

NCT07658222
View directory record Official record
Conditions
Cirrhotic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

NCT03515044
View directory record Official record
Conditions
Overt Hepatic Encephalopathy
Interventions
40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily, 80 mg Rifaximin SSD twice daily, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
34
States / cities
Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial to Improve Quality of Life in People With Cirrhosis

NCT05061992
View directory record Official record
Conditions
Cirrhosis
Interventions
Lactulose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated Phase 2 Interventional

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
View directory record Official record
Conditions
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions
VS-01 on top of SOC (Active Treatment Group), SOC
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 19, 2026, 7:03 PM EDT
Recruiting Not applicable Interventional

Affect of Melatonin on Sleep and Cognition in Cirrhosis

NCT07046429
View directory record Official record
Conditions
Hepatic Encephalopathy, Covert Hepatic Encephalopathy, Cirrhosis, Sleep Disturbances and Insomnia
Interventions
Melatonin tablet 3 mg once daily, Thiamine
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Not applicable Interventional

Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial

NCT03493204
View directory record Official record
Conditions
Hepatic Encephalopathy, Ascites, Liver Diseases, Cirrhosis
Interventions
Meal delivery, Standard pamphlet with Dietary Advice
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Factors Associated With End Stage Liver Disease

NCT01846819
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Fatigue, Depression
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

NCT01846663
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Not applicable Interventional

CAREGIVER: A Trial to Improve the Burden and Distress of Caring for Persons With Decompensated Cirrhosis

NCT04205396
View directory record Official record
Conditions
Caregivers
Interventions
Written emotional disclosure, Resilience training, No treatment
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated Not applicable Interventional

Cirrhosis Readmission Telehealth Project

NCT02313896
View directory record Official record
Conditions
Cirrhosis
Interventions
Phone calls
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Sep 19, 2026, 7:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy

NCT00686920
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Aurora, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated Phase 3 Interventional Results available

To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

NCT01829347
View directory record Official record
Conditions
Severe Acute Alcoholic Hepatitis
Interventions
ELAD, Standard of Care treatment
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Sep 19, 2026, 7:03 PM EDT
Terminated Phase 2 Interventional

Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

NCT04155099
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
RBX7455, Placebo
Biological
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jefferson, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Sep 19, 2026, 7:03 PM EDT
Recruiting Not applicable Interventional

Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy

NCT04096014
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Ensure Enlive, Standard Of Care
Dietary Supplement · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 19, 2026, 7:03 PM EDT